|
**Overview**: Chromosome Karyotype Couple Panel**Introduction**: The Chromosome Karyotype Couple Panel is a diagnostic tool designed to assess chromosomal compatibility using whole blood samples. In India, chromosomal abnormalities in couples (e.g., balanced translocations) cause recurrent pregnancy loss (RPL) in 2-5 percent of couples, with structural rearrangements in 2-5 percent of RPL cases. High morbidity from underdiagnosis in infertile couples, limited cytogenetics access in rural areas, delayed counseling leading to repeated losses. Per cytogenetics practices aligned with ICMR and FOGSI guidelines, the test employs karyotyping for chromosomal analysis over 1-2 days with high accuracy, valuable for detecting carriers and guiding reproductive options. This diagnostic falls under genetic screening and targets couples with RPL or infertility, addressing accurate detection to inform IVF/PGD or counseling. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification and reducing recurrent losses. Its whole blood-based approach ensures reliable detection.**Other Names**: Karyotype Couple Pnl.**FDA Status**: FDA approved, CLIA certified for cytogenetics, compliant with 2025 standards.**Historical Milestone**: Karyotyping standard; in India, essential in RPL clinics.**Purpose**: The test assesses 4 parameters including male/female karyotype to guide chromosomal compatibility evaluation, detect abnormalities, inform reproductive counseling.**Test Parameters**: 1. Male Karyotype, 2. Female Karyotype, 3. Chromosomal Abnormalities, 4. Compatibility Analysis.**Pretest Condition**: No fasting required; patients should report recurrent miscarriage or infertility.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for karyotyping).**Medical History**: Patients should provide details on pregnancy losses, infertility duration, family genetic history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of chromosomal abnormalities including recurrent loss, benefits of detection, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using karyotyping by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low cell growth can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal karyotype indicates carrier status, necessitating genetic counseling. Normal may require follow-up if history suggestive.**Specialist Consultation**: Geneticists or reproductive endocrinologists should be consulted for management.**Additional Supporting Tests**: CMA or FISH for confirmation.**Test Limitations**: Detects only gross abnormalities; comprehensive approach required.**References**: Indian Journal of Medical Genetics 2024, RPL Studies India 2023. |
